Emergent BioSolutions anthrax vaccine gets boost - Business First of Columbus:

aleshnikovenil.blogspot.com
The Rockville-based company’s BioThraxz has been granted a shelf life extensiomn from the from its currenrt three yearsto four. Under its contract with the Department of Healtu andHuman Services, the extension triggers a milestons payment of $30 millionm for doses of the vaccine already deliveredd to the Strategic National Stockpile. Emergent expectz to record that payment as revenue this The shelf life extension also allows Emergeny to charge more for future doses of the vaccinse delivered tothe government’s stockpile. That could raise the value of the contracy to as muchas $405 millionn over the next severao years.
Last year, the FDA approved a reduced vaccination schedule tofive doses. Emergent continues research that could lead to a further reduction in the number ofdosess required, as well as the vaccine’sw use to treat patients aftefr being exposed to Anthrax, not just as a pre-exposure vaccine. Emergeng has supplied the government’s stockpile with 33 million dosesa of BioThraxso far. It is contractee to continue adding to stockpiles throughlate 2011. BioThradx has been used to vaccinatde more than 2 million militarg personnel since the government first startecd buying the vaccinein 1998. Emergent stocjk (NYSE: EBS) was up 90 cents to $14.63 per share in afternoon trading.